A systematic review concludes that gut microbes, microbial metabolites and the hepatic immune environment may jointly influence the response of people with hepatocellular carcinoma to immune checkpoint inhibitors. The review maps how signals traveling through the gut–liver axis can affect liver inflammation, tumor immunity and immunotherapy resistance. It does not establish a new treatment: the evidence summarized is largely associative, causal relationships remain incompletely resolved, and the proposed microbial and metabolic interventions require prospective clinical testing and standardization.
The review, led by Professor Jun Yu at the Chinese University of Hong Kong, China, was published on October 8, 2026, in Immunity & Inflammation . It systematically examines evidence concerning gut microbial and metabolic modulation in hepatocellular carcinoma, focusing on the liver’s immune microenvironment and the efficacy of immune checkpoint inhibitors. Rather than treating any microorganism as universally beneficial or harmful, the review emphasizes that microbial effects depend on the underlying liver disease, tumor stage, immune context and local concentration of metabolites.
The scope is translational: it brings together biological mechanisms, candidate intervention strategies and the methodological obstacles that must be addressed before microbiome-based approaches can be applied clinically. The gut–liver axis provides a route through which intestinal conditions can influence liver immunity. Microbial products and metabolic signals reach the liver through the portal vein.
When microbial homeostasis is disrupted, intestinal barrier integrity can be compromised and permeability can increase, allowing pathogen-associated molecular patterns to reach the liver and activate innate immune cells. This may help sustain chronic inflammation. The review also discusses lipopolysaccharide, bile acids, short-chain fatty acids and tryptophan derivatives as microbial or microbial-derived molecules that can regulate oxidative stress and DNA damage, processes associated in the source material with cellular senescence, fibrosis and hepatocarcinogenesis.
Together, these observations frame the gut–liver axis as a regulatory network connecting barrier function, metabolism, immune-cell differentiation and antitumor responses rather than as a simple one-way metabolic conduit. Within the liver, immune checkpoint inhibitor efficacy depends on more than the expression of a target on tumor cells. The hepatic environment must also support an effective balance between immune populations that attack tumors and those that suppress them.
CD8-positive T cells, natural killer T cells, dendritic cells and innate lymphoid cells can participate in antitumor responses, while regulatory T cells, M2 macrophages and myeloid-derived suppressor cells can contribute to an immunosuppressive environment. The evidence discussed in the review suggests that gut microbial composition and microbial metabolites may influence this balance and could help explain why people receiving the same immunotherapy have different outcomes. This remains a proposed mechanistic link, not a clinically validated predictor of treatment response.
The review stresses that understanding mechanism is more informative than simply cataloguing which bacteria increase or decrease in patient samples. Short-chain fatty acids, bile-acid derivatives and tryptophan metabolites can affect antigen presentation, T-cell activation, myeloid-cell polarization and the inflammatory tone of the liver. Some microbial metabolites may enhance cytotoxic immune activity, while others may increase immunosuppression or contribute to resistance to checkpoint blockade.
Their effects are not inherent properties of the compounds in isolation; they vary with liver disease etiology, tumor stage, the host immune system and local metabolite concentrations. This dynamic relationship among microbes, their metabolic products and hepatic immunity is the central framework presented by the authors. Four broad intervention strategies are discussed as possible ways to rebuild a gut–liver ecosystem more compatible with antitumor immunity.
Probiotics and prebiotics are proposed as approaches for supporting intestinal barrier function, changing metabolite production and potentially lowering endotoxin exposure. Fecal microbiota transplantation is considered as a way to restore microbial functions associated with favorable immune responses through an ecological reset. Engineered bacteria and synthetic consortia could potentially deliver immunomodulatory molecules locally within tumors or regulate selected metabolic pathways.
The fourth strategy involves supplementation or pathway-level intervention using short-chain fatty acids, bile-acid derivatives and tryptophan metabolites as potential immune checkpoint inhibitor sensitizers. These proposals share an aim of supporting antigen presentation, effector T-cell activation and tumor immune clearance, rather than simply increasing the abundance of a single bacterium. None of the interventions is presented as an established method for improving immunotherapy outcomes in hepatocellular carcinoma.
Most existing clinical cohorts remain at the association level, and the review notes that causality has not been fully established. Diet, geography, cirrhosis severity, antibiotic exposure, sequencing platforms and the etiology of liver cancer can affect the reproducibility of microbiota findings. Standardization is also required for probiotic strain selection, donor screening in fecal microbiota transplantation and the construction of engineered bacteria.
Long-term safety and efficacy endpoints remain to be defined. These limitations mean that the review’s intervention categories are research directions rather than tested clinical prescriptions. The authors call for research frameworks that integrate multi-omics, mechanistic validation and prospective clinical trials.
Such work would connect the structure and function of microbial communities with measured metabolite profiles, local immune status and immunotherapy outcomes. Mechanistic studies can test whether a candidate microorganism or metabolite alters barrier function, immune-cell behavior or antitumor activity, while prospective studies can assess whether those changes are associated with response or resistance in defined clinical groups. Standardized sampling and analysis would help distinguish biologically meaningful signals from variations attributable to diet, medication, geography or disease severity.
The proposed framework is intended to move correlative discoveries toward actionable precision regimens, but that translation remains dependent on the research itself. The review ultimately presents gut microbial and metabolic modulation as one possible route to addressing resistance in liver cancer immunotherapy. Resistance may arise not only from features of tumor cells but also from the surrounding hepatic immune environment, which can be shaped by intestinal microbial activity.
The authors suggest that future advances may come from identifying effective tumor-surface targets, determining what support the gut microbiota provides and developing controllable interventions that reactivate otherwise silent antitumor responses. Integrating microbial composition, metabolite profiles and local immune status could eventually inform combination approaches in which immune checkpoint inhibitors work alongside ecosystem-based treatments. At present, that prospect rests on causal evidence, standardized methods and safety and efficacy data from prospective studies rather than on microbiome associations alone.
Subject of Research: Gut microbial and metabolic modulation of immunotherapy response in hepatocellular carcinoma
Article Title: Targeting the gut-liver axis: New review explores microbial modulation to enhance immunotherapy in hepatocellular carcinoma
Article References: Targeting the gut-liver axis: New review explores microbial modulation to enhance immunotherapy in hepatocellular carcinoma. Original publication (Bibliographic details unavailable.)
Image Credits: AI Generated
DOI: Not provided
Keywords: hepatocellular carcinoma, gut–liver axis, gut microbiota, microbial metabolites, cancer immunotherapy, immune checkpoint inhibitors, tumor immunity, fecal microbiota transplantation, probiotics, systematic review, Targeting, gut-liver
News Source: Nathaniel Bowman. (October 21, 2026). Research report: Targeting the gut-liver axis: New review explores microbial modulation to enhance immunotherapy in hepatocellular carcinoma. Scienmag.
